List view / Grid view

Julien Dodet

 

article

The future of targeted alpha therapy development and manufacture

Following the first industrial-scale facility for targeted alpha therapy (TAT)…

7 March 2024 | By

Following the first industrial-scale facility for targeted alpha therapy (TAT) production in Europe beginning construction, in this exclusive Q&A, Julien Dodet, CEO of Orano Med, elaborates on the key trends in radioligand therapeutics and why TATs hold significant advantages as cancer treatments.